olmesartan has been researched along with Hepatitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Buey, L; Rubín de Célix, C; Serrano, R | 1 |
| Ioshii, SO; Précoma, DB; Sturzeneker, MC; Villela Baroncini, LA | 1 |
2 other study(ies) available for olmesartan and Hepatitis
| Article | Year |
|---|---|
Acute hepatitis due to olmesartan: an uncommon entity.
Topics: Antihypertensive Agents; Blood Pressure; Female; Hepatitis; Humans; Hypertension; Imidazoles; Middle Aged; Tetrazoles | 2021 |
Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia.
Topics: Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol, Dietary; Disease Models, Animal; Fatty Liver; Hepatitis; Hypercholesterolemia; Imidazoles; Lipids; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Rabbits; Tetrazoles; Time Factors | 2011 |